The Filing Desk

Twist Bioscience

TWST · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

TWST · Last close · November 13, 2026
$111.60
Value Twist Bioscience yourself

Twist Bioscience's revenue rose 20.3% to $377 million in fiscal 2025. Its operating margin was −36.2%, up from −70.6% a year earlier. Free cash flow was −$76 million. The diluted share count rose 3.1%.

Twist Bioscience Corporation Latest fiscal year ended September 30, 2025 10-K filed November 17, 2025 · 0001581280-25-000025 Updated
Revenue
$377M
20.3%
Operating margin
−36.2%
34.4 pts
Net income
−$78M
 
Free cash flow
−$76M
 
Return on equity
−16.4%
21.6 pts
Market cap
$7.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What Twist Bioscience does

Twist Bioscience makes synthetic DNA. Its core technology "writes" DNA on a silicon chip, which lets it build more than a million short pieces of DNA on each chip. The company says this cuts the chemicals needed per gene compared with older plate-based methods. It combines the chips with its own software and an online ordering platform.

It sells synthetic genes, tools for next-generation sequencing (machines and methods that read DNA), sample preparation products, and products and services for drug discovery, such as antibody discovery. Its customers are researchers and companies in health care, chemicals and materials, food and agriculture, and academic research, in many countries. Nearly all of its revenue so far has come from its synthetic DNA products, and it says it needs to grow its synthetic biology and sequencing product groups and spread into other areas.

Twist says it competes in a crowded field and that losing a few large customers could hurt its revenue. Its fiscal year ends on September 30.

Its biggest risks, as it describes them

  • It has lost money in every period so far and may never become profitable.
  • Nearly all its revenue comes from synthetic DNA products, so it depends on their continued success.
  • It could lose a few large customers, which would cut its revenue.
  • It competes in a crowded industry, and rivals may develop technology that replaces its products.
  • It may be unable to keep revenue growing or to manage that growth.
From Twist Bioscience's annual report on Form 10-K, filed November 17, 2025, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Twist Bioscience lost money in fiscal 2025: a net loss of $78 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments478505336276232
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−416.1x−2,934.7x−43,431.8x−7,614.9x—
Current ratio8.7x6.6x5.8x4.9x3.6x
Quick ratio8.2x6.2x5.3x4.5x3.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project Twist Bioscience's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Twist Bioscience shares on the open market, and 10 insiders sold $126.1 million, $110.8 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 24, 2026Emily M. LeproustChief Executive Officer, DirectorSold plan5,203$177.38$922,899Form 4
Sep 21, 2026Emily M. LeproustChief Executive Officer, DirectorSold1,687$165.49$279,182Form 4
Sep 21, 2026Dennis ChoSee RemarksSold348$165.49$57,591Form 4
Sep 21, 2026Paula GreenSVP of Human ResourcesSold294$165.49$48,654Form 4
Sep 17, 2026Emily M. LeproustChief Executive Officer, DirectorSold plan356,546$157.99$56.3 millionForm 4
Sep 8, 2026Emily M. LeproustChief Executive Officer, DirectorSold2,302$122.62$282,271Form 4
Sep 8, 2026Paula GreenSVP of Human ResourcesSold907$122.62$111,216Form 4
Sep 8, 2026Dennis ChoSee RemarksSold412$122.62$50,519Form 4
Sep 8, 2026Robert F. WernerChief Accounting OfficerSold238$122.62$29,184Form 4
Aug 25, 2026Emily M. LeproustChief Executive Officer, DirectorSold plan41,570$151.98$6.3 millionForm 4
Aug 24, 2026Robert F. WernerChief Accounting OfficerSold854$140.77$120,218Form 4
Aug 21, 2026Emily M. LeproustChief Executive Officer, DirectorSold6,639$139.07$923,286Form 4
The latest 12 of 117 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−49.0%5.6%0.2%
Altman Z''1.03−2.56−2.72
Accruals ratio−7.2%−20.8%−4.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Twist Bioscience side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Twist BioscienceFY2520.3%−36.2%−20.1%———
Krystal BiotechFY2533.9%41.5%48.5%43.6%−5.0x5Compare
Arrowhead PharmaceuticalsFY26−45.6%−156.9%−63.0%——2Compare
Tarsus PharmaceuticalsFY25146.7%−15.7%−4.9%——4Compare
ADMA BiologicsFY2519.6%37.5%5.5%39.5%−0.1x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue11255490132204245313377
Revenue growth—136.2%113.9%65.7%46.9%53.8%20.4%27.7%20.3%
Gross profit−13−7729528490133191
Research and development19203643691201079180
Operating income−58−71−109−140−153−235−217−221−136
Net income−59−71−108−140−152−218−205−209−78
Diluted EPS (US$)−24.49−25.51−3.92−3.57−3.15−4.04−3.60−3.60−1.30
Diluted shares (millions)2,422028394854575860
Cash flow
Cash from operations−51−66−88−142−112−124−142−64−48
Capital expenditure7415102710228528
Free cash flow−58−70−103−152−139−226−170−69−76
Dividends paid000000000
Share buybacks000000000
Acquisitions000008000
Stock-based compensation2311173780305164
Balance sheet at fiscal year end
Cash and short-term investments3181138290478505336276232
Debt incl. finance leases—1084—————
Total assets—116187399702961776614642
Total liabilities—273563121172153142169
Shareholders' equity−133−201152336581789623473473
Margins and ratios
Gross margin−123.1%−26.6%12.8%31.9%39.1%41.4%36.6%42.6%50.7%
Operating margin−543.2%−277.5%−200.2%−155.5%−115.4%−115.3%−88.6%−70.6%−36.2%
Net margin−550.9%−280.2%−198.0%−155.3%−114.9%−107.0%−83.5%−66.7%−20.6%
Free cash flow margin−537.7%−274.7%−188.8%−168.8%−105.3%−111.1%−69.5%−22.1%−20.1%
Rule of 40 (growth + FCF margin)—−138.6%−74.9%−103.2%−58.4%−57.3%−49.0%5.6%0.2%
Return on capital———−307.8%—————
Return on equity———−57.3%−33.2%−31.8%−29.0%−38.1%−16.4%
Return on assets——−71.1%−47.8%−27.6%−26.2%−23.6%−30.0%−12.4%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Twist Bioscience's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Twist Bioscience.